Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. (Q50949304)

25 March 2018

title

Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. (English)

1 reference

25 March 2018

Erratum: Elimination of large tumors in mice by mRNA-encoded bispecific antibodies.

1 reference

corrigendum / erratum

0 references

author

Uğur Şahin

9

1 reference

25 March 2018

Özlem Türeci

8

Özlem Türeci

1 reference

25 March 2018

Katalin Karikó

7

Katalin Karikó

1 reference

25 March 2018

1

Christiane R Stadler

1 reference

25 March 2018

Hayat Bähr-Mahmud

2

Hayat Bähr-Mahmud

1 reference

25 March 2018

Leyla Celik

3

Leyla Celik

1 reference

25 March 2018

Bernhard Hebich

4

Bernhard Hebich

1 reference

25 March 2018

Alexandra K Roth

5

Alexandra S Roth

1 reference

25 March 2018

René Roth

6

René P Roth

1 reference

25 March 2018

language of work or name

English

0 references

publication date

12 June 2017

1 reference

25 March 2018

published in

Nature Medicine

1 reference

25 March 2018

volume

23

1 reference

25 March 2018

page(s)

815-817

1 reference

25 March 2018

issue

7

1 reference

25 March 2018

https://scigraph.springernature.com/pub.10.1038/nm.4356

exact match

0 references

cites work

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

1 reference

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

21 January 2018

1 reference

Alternative molecular formats and therapeutic applications for bispecific antibodies

21 January 2018

1 reference

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

mRNA-based therapeutics--developing a new class of drugs

21 January 2018

1 reference

Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA

21 January 2018

1 reference

Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability

21 January 2018

1 reference

Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation

21 January 2018

1 reference

Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA.

21 January 2018

1 reference

Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells.

21 January 2018

1 reference

Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer

21 January 2018

1 reference

Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development

21 January 2018

1 reference

Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6

21 January 2018

1 reference

High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting.

21 January 2018

1 reference

The use of hybrid hybridomas to target human cytotoxic T lymphocytes.

21 January 2018

1 reference

The tobacco etch viral 5' leader and poly(A) tail are functionally synergistic regulators of translation

21 January 2018

1 reference

Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond

21 January 2018

1 reference

Bispecific antibodies rise again

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28604701

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NM.4356

1 reference

25 March 2018

PubMed ID

28604701

1 reference

25 March 2018